Search for: "UPSHER SMITH LABORATORIES INC"
Results 1 - 15
of 15
Sorted by Relevance
|
Sort by Date
6 Dec 2006, 6:01 am
said a U.S. federal court (D NJ) granted a temporary restraining order [TRO] enjoining all sales of generic oxandrolone tablets by Novartis AG'S Sandoz Pharmaceuticals, and Upsher-Smith Laboratories. [read post]
6 Dec 2013, 2:24 pm
Upsher-Smith Laboratories, Inc., Civ. [read post]
2 May 2016, 9:59 pm
Links to each of the filed briefs can be found below: • Brief for Amici Curiae Eli Lilly and Company, Eisai Inc., Upsher-Smith Laboratories, Inc., Pfizer Inc., and Etiometry, Inc. in Support of Petitioner (brief) • Brief of Amicus Curiae by The Chartered Institute... [read post]
19 Apr 2016, 7:43 am
Eli Lilly is joined in this brief by Eisai Inc., Upsher-Smith Laboratories, Inc., Pfizer Inc., and Etiometry, Inc. [read post]
16 Jul 2018, 3:02 am
Upsher-Smith Laboratories, Inc., No. 2:16-cv-02604 (6th Cir. [read post]
31 Jul 2012, 7:25 am
The plaintiffs are challenging settlements between Schering-Plough Corporation, the patent holder and manufacturer of K-Dur 20, and Upsher Smith Laboratories and ESI Lederle (“ESI”), which sought to market generic versions of the drug. [read post]
16 Jul 2009, 2:09 am
District Court by Upsher-Smith Laboratories, a pharmaceutical company. [read post]
19 May 2011, 12:20 pm
This case is an antitrust challenge to an agreement settling patent litigation between defendant-appellee Schering-Plough Corp.2 ("Schering") and defendant-appellee Upsher-Smith Laboratories, Inc. [read post]
24 Aug 2012, 7:46 pm
Some 11 years before that expiration date, in August 1995, Upsher-Smith Laboratories, a generic manufacturer, asked the federal government to approve for marketing a generic version of K-Dur. [read post]
FTC and California AG Join in Challenging Reverse Payment Settlements in the Pharmaceutical Industry
6 Mar 2009, 7:03 am
In 2001, the FTC issued an administrative complaint charging Schering-Plough Corp., Upsher-Smith Laboratories and American Home Products Corp. with similar violations of Section 1 of the Sherman Act and Section 5 of the FTC Act. [read post]
29 Aug 2012, 10:09 pm
(“Merck”) (formerly Schering-Plough Corporation) restricted competition in violation of the Sherman Act by settling patent infringement lawsuits against potential generic K-DUR entrants, including Upsher-Smith Laboratories (“Upsher-Smith”). [read post]
13 Sep 2012, 4:26 pm
., No. 12-245, and Upsher-Smith Laboratories, Inc. v. [read post]
25 Apr 2012, 1:56 pm
The FTC’s brief urges the Third Circuit to reverse a decision of the federal district court in New Jersey granting summary judgment ((CCH) 2010-1 Trade Cases ¶76,949) in favor of the patent holder, Schering-Plough Corporation, and the alleged infringers–Upsher Smith and ESI. [read post]
1 Feb 2008, 12:00 am
: (IPBiz),State of the Union address 28 Jan 2008: statement regarding patenting human life: (IPBiz), (Patently-O),Alnylam Pharmaceuticals secures UK patent covering molecules that affect RNA interference: (SmartBrief),Doha style compulsory licences for exports: The politics…: (Spicy IP),Pushing to compulsory licensing: Pharma companies heading closer to Doha: (Spicy IP),Financial Express on the battle between big pharma companies and the generic… [read post]
16 Aug 2008, 2:43 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Belgium - eBay wins ruling against L’Oreal in dispute over liability for counterfeit goods sold in online auctions: (Managing Intellectual Property), (Counterfeit Chic), (IPKat), (Class 46), (Techdirt), (Ars Technica) US CAFC holds that copying free software without complying with license is copyright infringement: Robert Jacobsen v… [read post]
